Patent EP1371986A1 successfully refreshed from Google Patents.
EP1371986A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Diagnosis of Alzheimer's disease based on the hAbeta42:hAbeta40 ratio
Assignee: Genetics Co Inc
•
Filing: 2002-06-06
•
Granted: —
•
Expires: 2022-06-06
Abstract
Abstract Described is a method for the diagnosis of Alzheimer's Disease (AD) or of a risk for developing said disease which is based on the determination of the ratio of hAß42:hAß40 (Aß42/40-ratio). A lower Aß42/40-ratio as compared to the normal ratio is indicative for AD or for a risk for developing AD. Moreover, kits are described suitable for carrying out said diagnostic method.
Inventors
- 👤 Tobias Dr. Hartmann
- 👤 Oliver Dr. Eikenberg
- 👤 Christof Dr. Antz
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-01 22:57
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/68; G01N33/6893; G01N33/6896; G01N2800/00; G01N2800/28; G01N2800/2814; G01N2800/2821
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
69 words
A method for the diagnosis of Alzheimer's Disease (AD) or of
a risk for developing said disease, comprising the following
steps: (a)contacting a sample with probes specifically binding to
hAβ42 and hAβ40, respectively; and (b) determining the amounts of hAβ42 and hAβ40 in said
sample, wherein a lower ratio of hAβ42:hAβ40 (Aβ42/40-ratio)
as compared to the normal ratio is indicative for AD or for
a risk for developing AD
Claim 2
Dependent Claim
36 words
The method of claim 1, wherein the ratio of hAβ42:hAβ40
(Aβ42/40-ratio) is less or equal 0.8 times compared to the mean
value of the normal ratios obtained by a population of at least
10 healthy individuals.
Claim 3
Dependent Claim
36 words
The method of claim 2, wherein the ratio of hAβ42:hAβ40
(Aβ42/40-ratio) is less or equal 0.6 times compared to the mean
value of the normal ratios obtained by a population of at least
10 healthy individuals.
Claim 4
Independent Claim
15 words
The method of any one of claims 1 to 3, wherein the sample is
CSF.
Claim 5
Independent Claim
21 words
The method of any one of claims 1 to 4, wherein the probes
are antibodies specific for hAβ42 and hAβ40, respectively.
Claim 6
Dependent Claim
37 words
The method of claim 5, wherein the anti-hAβ1-42-antibody is
directed to the epitope of hAβ42 at amino acid positions 35-42
(MVGGVVIA) and the anti-hAβ40-antibody is directed to the
epitope of hAβ40 at amino acid positions 33-40 (GLMVGGVV).
Claim 7
Dependent Claim
13 words
The method of claim 5 or 6, wherein the antibodies are
monoclonal antibodies.
Claim 8
Dependent Claim
10 words
The method of claim 5, wherein the anti-hAβ1-42-antibody is
G2-13.
Claim 9
Independent Claim
18 words
The method of any one of claims 5 to 8, wherein the method is
carried out as ELISA.
Claim 10
Dependent Claim
11 words
The method of claim 9, wherein the ELISA is a sandwich-ELISA.
Claim 11
Independent Claim
22 words
The method of any one of claims 1 to 10, comprising the
determination of the concentration of at least one additional
biomarker.
Claim 12
Dependent Claim
51 words
A kit suitable for carrying out the method according to any
one of claims 1 to 11 comprising a first monoclonal anti-hAβ42-antibody
directed to the epitope of hAβ42 at amino acid
positions 35-42 (MVGGVVIA) and a second monoclonal anti-hAβ40-antibody
directed to the epitope of hAβ40 at amino acid
positions 33-40 (GLMVGGVV).
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.